Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 6/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | BAX | Q07812 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28064507 | 0.87 | LTA4H (0.55) | ATMLTA4HTSHRNPC1RAB9A | |
| SCHEMBL28130528 | 0.85 | LTA4H (0.57) | ATMLTA4HTSHRGSTP1NR1H2 | |
| SCHEMBL24710880 | 0.82 | LTA4H (0.60) | ATMLTA4HTSHRKMT2ANR1H2 | |
| SCHEMBL197414 | 0.82 | LTA4H (0.75) | LTA4HTSHRNPC1RAB9AGSTP1 | |
| SCHEMBL6406035 | 0.82 | LTA4H (0.75) | LTA4HTSHRNPC1RAB9AGSTP1 | |
| SCHEMBL2860844 | 0.82 | LTA4H (0.75) | LTA4HTSHRNPC1RAB9AGSTP1 | |
| SCHEMBL21345911 | 0.82 | NPSR1 (0.53) | ATMLTA4HNPC1RAB9AMEN1 | |
| SCHEMBL7013344 | 0.80 | CYP11B2 (0.60) | LTA4HCYP2A6CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL9149482 | 0.79 | GSTP1 (0.45) | ATMLTA4HTSHRNPC1RAB9A | |
| SCHEMBL21921128 | 0.79 | LTA4H (0.71) | LTA4HTSHRNPC1RAB9AGSTP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2022-11-08 | — | — | US | disclosed |
| CN-1147492-C | New metal protease inhibitors, its preparing method and their medicinal composition containing them | ɪά��ʵ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1065209-B1 | Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-05-02 | — | — | EP | disclosed |
| US-6339092-B1 | FOR THERAPY RHEUMATOID ARTHRITIS, ARTHROSIS, TUMOUR INVASION AND GROWTH, INCLUDING MALIGNANT SPREAD AND THE FORMATION OF METASTASES, ULCERATIONS, ATHEROSCLEROSIS | ADIR ET COMPAGNIE (FR) | 2002-01-15 | — | — | US | disclosed |
| EP-1065209-A1 | Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | ATM 392/4885LTA4H 1863/4885TSHR 2994/4885 |
| US-11491153-B2 | Methods for treating cancer using pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | ATM 392/4885LTA4H 1863/4885TSHR 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.